Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study

Mutagenesis

Volumn 18, Issue 5, 2003, Pages 457-463

  Marshall, R ^a   Tricta, F ^b   Galanello, R ^c   Leoni, G ^c   Kirkland, David ^a   Minto, S ^a   Spino, M ^b  

^a UK   (United Kingdom)

^b Apotex Inc   (Canada)

^c Territorial Department of Nephrology and Dialysis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; IRON; IRON CHELATING AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FREQUENCY ANALYSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; LYMPHOCYTE; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; SAMPLING; SEX DIFFERENCE; STAINING; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CELL CYCLE; CHELATION THERAPY; CHROMOSOME ABERRATIONS; CROSS-OVER STUDIES; DEFEROXAMINE; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IRON CHELATING AGENTS; MALE; MUTAGENS; PYRIDONES;

EID: 0041878604     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/geg014     Document Type: Article

References (30)

1. Anderson,D., Yardley-Jones,A., Vives-Bauza,C., Chua-Anusom,W., Cole,C. and Webb,J. (2000) Effect of iron salts, haemosiderins and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay. Teratog. Carcinog. Mutagen., 20, 251-264.
2. Aruoma,O.I., Helliwell,B., Laughton,M.J., Quinlan,G.J. and Gutteridge,J.M. (1989) The mechanism of initiation of lipid peroxidation. Evidence against a requirement for an iron(II)-iron(III) complex. Biochem. J., 258, 617-620.
3. Balla,G., Vercellotti,G.M., Eaton,J.W. and Jacob,H.S. (1990) Iron loading of endothelial cells augments oxidant damage. J. Lab. Clin. Med., 116, 546-554.
4. Beall,H.D., Liu,Y., Siegel,D., Bolton,E.M., Gibson,N.W. and Ross,D. (1996) Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol., 51, 645-652.
5. Bruce,W.R. and Heddle,J.A.(1979) The mutagenic activity of 61 agents as determined by the micronucleus, salmonella and sperm abnormality assays. Can. J. Genet. Cytol., 21, 319-334.
6. Chenoufi,N., Hubert,H., Loréal,O., Morel,I., Pasdeloup,N., Cillard,J., Brissot,P. and Lescoat,G. (1995) Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94. J. Hepatol., 23, 166-173.
7. Côté,G.B. and Papadakou-Lagoyanni,S. (1979) β-Thalassaemia: increased chromosomal anomalies in lymphocyte cultures. J. Med. Genet., 16, 52-55.
8. Cragg,L., Hebbel,R.P., Miller,W., Solovey,A., Selby,S. and Enright,H. (1998) The iron chelator L1 potentiates oxidative DNA damage in iron-overloaded liver cells. Blood, 92, 632-638.
9. Dunkel,V.C., San,R.H.C., Seifried,H.E. and Whitaker,P. (1999) Genotoxicity of iron compounds in Salmonella typhimurium and L5178Y mouse lymphoma cells. Environ. Mol. Mutagen., 33, 28-41.
10. Gille,J.J., van Berkel,C.G. and Joenje,H. (1992) Effect of iron chelators on the cytotoxic and genotoxic action of hyperoxia in Chinese hamster ovary cells. Mutat. Res., 275, 31-39.
11. Giri,A.K. (1993) The genetic toxicology of paracetamol and aspirin: a review. Mutat. Res., 296, 199-210.
12. 1 cells. Am. J. Physiol., 27, 209-215.
13. Hart,J.W. and Hartley-Asp,B. (1983) Induction of micronuclei in the mouse. Revised timing of the final stage of erythropoesis. Mutat. Res., 120, 127-132.
14. Hartwig,A. and Schlepegrell,R. (1995) Induction of oxidative DNA damage by ferric iron in mammalian cells. Carcinogenesis, 16, 3009-3013.
15. Hartwig,A., Schlepegrell,R. and Beyersmann,D. (1992) Genotoxicity of Fe (III)-NTA in mammalian cells. Mutagenesis, 7, 159.
16. Juckett,M.B., Shadley,J.D., Zheng,Y. and Klein,J.P. (1998) Desferrioxamine enhances the effects of gamma radiation on clonogenic survival and the formation of chromosomal aberrations in endothelial cells. Radiat. Res., 149, 330-337.
17. 2 phase irradiation. Int. J. Radiat. Biol., 66, 29-39.
18. Matthews,A.J., Vercellotti,G.M., Menchaca,H.J., Bloch,P.H.S., Michaleck,V.N., Marker,P.H., Murar,J. and Buchwald,H. (1997) Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J. Surg. Res., 73, 35-40.
19. Mitelman,F. (ed.) (1995) An International System for Human Cytogenetic Nomenclature. Karger, Basel, Switzerland.
20. Morel,I., Cillard,J., Lescoat,G., Sergent,O., Pasdeloup,N., Ocaktan,A., Abdallah,M.A., Brissot,P. and Cillard,P. (1992) Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic. Biol. Med., 13, 499-508.
21. Morel,I., Sergent,O., Cogre],P., Lescoat,G., Pasdeloup,N., Brissot,P., Cillard,P. and Cillard,J. (1995) EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radic. Biol. Med., 18, 303-310.
22. Niihara,Y., Ge,J., Shalev,O., Hebbel,R.P. and Tanaka,K.R. (1998) Desferal (DFO) incubation of intact red blood cell (RBC) leads to decrease in NAD redox potential: evidence for Desferal as an inducer of oxidant stress in intact RBC. Blood, 92, 7b.
23. Shalev,O., Repka,T., Goldfarb,A., Grinberg,L., Abrahamov,A., Olivieri,N.F., Rachmilewitz,E.A. and Hebbel,R.P. (1995) Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood, 86, 2008-2013.
24. Stinson,T.J., Jaw,S., Jeffery,H. and Plewa,M.J. (1992) The relationship between nickel chloride-induced peroxidation and DNA strand breakage in rat liver. Toxicol. Appl. Pharmacol., 117, 98-103.
25. Swiger,R.R. and Tucker,J.D. (1996) Fluorescence in situ hybridisation: a brief review. Environ. Mol. Mutagen., 27, 245-254.
26. Tucker,J.D., Lee,D.A., Ramsey,M.J., Briner,J., Olsen.L. and Moore,D.H. (1994) On the frequency of chromosome exchanges in a control population measured by chromosome painting. Mutat. Res., 313, 193-202.
27. van der Kraaij,A.M.M., van Eijk,H.G. and Koster,J.F. (1989) Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-cimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation, 80, 158-164.
28. Vig,B.K. and Eyring,E.J. (1971) Absence of chromosome aberrations in cultured human leukocytes treated by two metal chelators-deferoxamine and penicillamine. Mutat. Res., 12, 214-218.
29. Whittaker,P., Seifried,H.E., San,R.H.C., Clarke,J.J. and Dunkel,V.C. (2001) Genotoxicity of iron chelators in L5178Y mouse lymphoma cells. Environ. Mol. Mutagen., 38, 347-356.
30. Whiting,R.F., Wei,L. and Stich,H.F. (1981) Chromosome damaging activity of ferritin and its relation to chelation and reduction of iron. Cancer Res., 41, 1628-1636.